Summary iBio Inc (iBio) is a biotechnology company that develops and manufactures plant made pharmaceutical products. The company offers products such as biotherapeutics and vaccines. It uses its ibiolaunch platform, which is a transformative technology for the production of monoclonal antibodies, other therapeutic proteins and vaccines. iBio is developing therapeutic product for the treatment of idiopathic pulmonary fibrosis, systemic scleroderma and other fibrotic diseases. The company's IBIO-CFB03 is helpful for the treatment of idiopathic pulmonary fibrosis, fibrotic diseases and systemic sclerosis. It collaborates with medical universities for its research and development activities. iBio is headquartered in New York, the US. iBio Inc (IBIO) - Pharmaceuticals & Healthcare - Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into... Research Beam Model: Research Beam Product ID: 2032720 250 USD New
iBio Inc (IBIO) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
 
 

iBio Inc (IBIO) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

  • Category : Company Profiles
  • Published On : August   2017
  • Pages : 47
  • Publisher : GlobalData
 
 
 
Summary

iBio Inc (iBio) is a biotechnology company that develops and manufactures plant made pharmaceutical products. The company offers products such as biotherapeutics and vaccines. It uses its ibiolaunch platform, which is a transformative technology for the production of monoclonal antibodies, other therapeutic proteins and vaccines. iBio is developing therapeutic product for the treatment of idiopathic pulmonary fibrosis, systemic scleroderma and other fibrotic diseases. The company's IBIO-CFB03 is helpful for the treatment of idiopathic pulmonary fibrosis, fibrotic diseases and systemic sclerosis. It collaborates with medical universities for its research and development activities. iBio is headquartered in New York, the US.

iBio Inc (IBIO) - Pharmaceuticals & Healthcare - Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals - Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year - Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type - Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region - Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector - Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals - Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description - A brief description of the company's operations.
- Key Employees - A list of the key executives of the company.
- Important Locations and Subsidiaries - A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors - A list of the key competitors of the company.
- Key Recent Developments - A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements
- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy
- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.
Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
iBio Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
iBio Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
iBio Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
iBio Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 9
iBio Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 10
iBio Inc, Pharmaceuticals & Healthcare, Deal Details 12
Asset Purchase 12
iBio Acquires Orphan Drug Designation And Related Property Rights From Kentucky Bioprocessing 12
Partnerships 13
Texas A&M University Enters into Agreement with iBio 13
iBio Amends Agreement with Medical University of South Carolina 14
iBio Amends Co-Development Agreement With Fraunhofer 15
Ibio Enters Into Agreement With GE Healthcare To Commercialize Plant-Based Technologies 16
iBio Enters into Agreement with Novici Biotech 17
Licensing Agreements 18
iBio Amends Licensing Agreement with US University 18
iBio Enters into Licensing Agreement with Caliber Biotherapeutics 19
iBio Extends Licensing Agreement with Fraunhofer 20
iBio Extends its Licensing Agreement with Bio-Manguinhos 21
iBio Enters into Licensing Agreement with University of Pittsburgh 22
iBio Enters Into Licensing Agreement With Caliber Biotherapeutics 23
iBio Enters Into Licensing Agreement With Bio-Manguinhos 24
Equity Offering 25
iBio to Raise Funds in Public Offering of Shares 25
iBio Raises USD1 Million in First Tranche of Private Placement of Shares 26
iBio Raises USD4 Million in Second and Final Tranche of Private Placement of Shares 28
iBio Raises USD2.2 Million in First Tranche of Private Placement of Shares 29
iBio Raises USD1 Million in Private Placement of Shares up on Exercise of Warrants 30
iBio Plans to Raise up to USD15 Million in Private Placement of Shares 31
iBio Raises USD10 Million in Private Placemet of Shares 32
iBio Raises USD0.5 Million in First Tranche of Private Placement of Shares 33
Ibio Completes Public Offering Of Units For US$4 Million 34
ibio Announces Private Placement Of Shares For Up To US$10 Million 35
iBio, Biotechnology Company, Completes Public Offering Of Common Stock For US$10 Million 36
iBio Inc - Key Competitors 37
iBio Inc - Key Employees 38
iBio Inc - Locations And Subsidiaries 39
Head Office 39
Recent Developments 40
Legal and Regulatory 40
Aug 15, 2016: Implications of Court Decision in Favor of iBio Against Fraunhofer 40
Aug 08, 2016: Delaware Chancery Court confirms Fraunhofer USA Rights 42
Aug 04, 2016: iBio's Claims Against Fraunhofer Affirmed by Delaware Chancery Court 43
Product News 44
Sep 29, 2016: iBio Proprietary Technology Advances Neonatal Respiratory Distress Syndrome Drug Development for South African Biotech Company AzarGen Biotechnologies 44
Other Significant Developments 45
May 04, 2017: iBio Provides Corporate Update at Annual Shareholders Meeting 45
Appendix 47
Methodology 47
About GlobalData 47
Contact Us 47
Disclaimer 47

List of Tables
iBio Inc, Pharmaceuticals & Healthcare, Key Facts, 2016 2
iBio Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
iBio Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
iBio Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
iBio Inc, Deals By Therapy Area, 2011 to YTD 2017 9
iBio Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 10
iBio Acquires Orphan Drug Designation And Related Property Rights From Kentucky Bioprocessing 12
Texas A&M University Enters into Agreement with iBio 13
iBio Amends Agreement with Medical University of South Carolina 14
iBio Amends Co-Development Agreement With Fraunhofer 15
Ibio Enters Into Agreement With GE Healthcare To Commercialize Plant-Based Technologies 16
iBio Enters into Agreement with Novici Biotech 17
iBio Amends Licensing Agreement with US University 18
iBio Enters into Licensing Agreement with Caliber Biotherapeutics 19
iBio Extends Licensing Agreement with Fraunhofer 20
iBio Extends its Licensing Agreement with Bio-Manguinhos 21
iBio Enters into Licensing Agreement with University of Pittsburgh 22
iBio Enters Into Licensing Agreement With Caliber Biotherapeutics 23
iBio Enters Into Licensing Agreement With Bio-Manguinhos 24
iBio to Raise Funds in Public Offering of Shares 25
iBio Raises USD1 Million in First Tranche of Private Placement of Shares 26
iBio Raises USD4 Million in Second and Final Tranche of Private Placement of Shares 28
iBio Raises USD2.2 Million in First Tranche of Private Placement of Shares 29
iBio Raises USD1 Million in Private Placement of Shares up on Exercise of Warrants 30
iBio Plans to Raise up to USD15 Million in Private Placement of Shares 31
iBio Raises USD10 Million in Private Placemet of Shares 32
iBio Raises USD0.5 Million in First Tranche of Private Placement of Shares 33
Ibio Completes Public Offering Of Units For US$4 Million 34
ibio Announces Private Placement Of Shares For Up To US$10 Million 35
iBio, Biotechnology Company, Completes Public Offering Of Common Stock For US$10 Million 36
iBio Inc, Key Competitors 37
iBio Inc, Key Employees 38
List of Figures
iBio Inc, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017 2
iBio Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 2
iBio Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 2
iBio Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 2
iBio Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
iBio Inc, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017 7
iBio Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
iBio Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 9
PURCHASE OPTIONS
 
 
 

How can we help you?

Contact us at the Consulting WP office nearest to you or submit a business inquiry online.


  Contact
 

Subscribe to Our Newsletter